Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.

Kittredges continue generous support of melanoma and immuno-oncology research

Patrick Ott, MD, PhD

Summer 2024
By Michael Quinn
Photography by Sam Ogden

Francis Kittredge, MD, JD, and his wife, Adele, know that supporting Dana-Farber Cancer Institute makes a difference because their philanthropy already has—and their impact continues to grow through their ongoing generosity.

Recently the couple made a gift of $500,000 to advance cancer vaccine research led by Patrick Ott, MD, PhD, clinical director of the Melanoma Center and clinical science director of the Center for Immuno-Oncology at Dana-Farber. This latest gift brings their cumulative giving to an incredible $1 million.

The Kittredges’ first major gift to Dana-Farber accelerated the NeoVax clinical trial led by Ott that provided the first proof-of-concept for personalized vaccines in treating melanoma. The trial was so successful that the immune response kindled by the vaccine in participants remained robust and effective against melanoma four years later and counting, per Ott’s follow-up study. The Kittredges’ support played such an integral role in this landmark achievement that they were acknowledged by Dr. Ott in the study paper published in Nature Medicine.

“It is a privilege to support Dr. Ott’s outstanding work and we know it will continue to improve the lives of patients everywhere.”

Francis Kittredge, MD, JD

Now, with their new gift, the Kittredges are enabling Ott to pursue novel trials of melanoma vaccines in combination with other agents to enhance their efficacy and benefit more patients. According to Ott, the Kittredges’ generosity was instrumental in bringing his work this far and remains pivotal to further progress, saying, “Dr. and Mrs. Kittredge have been wonderful partners, and the lives extended by the research they support attest to their indelible impact.”  

As strong supporters of Ott’s, Dr. and Mrs. Kittredge are pleased that their philanthropy is fueling advances against melanoma while also unlocking promising new treatments for other diseases like brain cancer. He said: “It is a privilege to support Dr. Ott’s outstanding work and we know it will continue to improve the lives of patients everywhere.”

,
Copy link
Powered by Social Snap